William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Hedge funds that crowded into same names likely to nurse losses
-
Ackman's hedge fund down 13.1 percent for August
-
Ackman says Pershing Square down for the year after markets drop
-
Ackman's Pershing Square Liquidates Actavis Stake in Q2 - 13F
-
Highlights from Pershing Square's Q2 Conf. Call; Bought Mondelez (MDLZ) Hand-Over-Fist, Hasn't Engaged China About Herbalife (HLF)
-
Hearing Nothing New in Zoetis (ZTS) Takeover Story, CNBC's David Faber Reports
-
StreetInsider Top 50 Takeover Targets Notable Changes 6/25: (ZTS)
-
Ackman's Pershing Square Boosts Zoetis (ZTS) Stake; Takes Positions in Actavis (ACT), Valeant (VRX) - 13F
-
Jarden (JAH) Undervalued, Says Ackman at Sohn
-
Zoetis (ZTS) Has Great 'Stand Alone' Value - Ackman
-
Zoetis (ZTS) Off Lows as Ackman to Discuss Acquisitions/JVs with Valeant (VRX)
-
Zoetis (ZTS) Gains on Ackman Valeant News
-
Ackman's Pershing Square Granted Early Antitrust Approval for Deal Involving Zoetis (ZTS)
-
Zoetis (ZTS) Confirms Bill Ackman Call; No Comment on Details of Conversation
-
Zoetis (ZTS) Active: Pershing Square Takes Stake - DJ
-
Allergan (AGN) Files to Block Ackman's Pershing Square from Voting at Dec. Meeting (VRX)
-
Pershing Square Submits Additinal Special Meeting Requests to 1.29% of Allergan (AGN) Shareholders
-
Ackman's Pershing Square Approved to Call Special Meeting of Allergan (AGN) Shareholders (VRX)
-
Valeant Pharmaceuticals (VRX), Pershing Call Allergan (AGN) Lawsuit Frivolous
-
Valeant Pharma (VRX) price drop a buying opportunity, Bill Ackman tells CNBC
-
Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha
-
Pershing Square Taps Top Global Bank in Effort to Bring Valeant (VRX) and Allergan (AGN) Together
-
Pershing's Lawsuit Against Alergan (AGN) Fast-Tracked - WSJ
-
Valeant Pharmaceuticals (VRX), Pershing Square Revise Offer for Allergan; Now $72/Share Cash, 0.82 of Valeant Stock
-
Pershing Square Sends Letter to Allergan, Inc. (AGN); Sees Fault in Rejecting Valeant (VRX) Offer
-
Top 10 News for 04/21 - 04/25: Valeant Makes Big Acquisition; EPS Galore; Netflix Mulls Price Hike
-
TD Securities Upgrades Valeant Pharmaceuticals (VRX) to Buy
-
Pre-Open Movers 4/22: (RVNC) (AGN) (NFLX) Higher; (MDSO) (BEBE) (RMBS) Lower (more...)
-
After-Hours Movers 4/21: (AGN) (VRX) (NFLX) Higher; (RMBS) (CDNS) (ALSN) Lower (more...)
-
Market Wrap: Next Ford CEO Speculated; Gold Merger Tarnishes; Sarepta Pops on DMD Treatment Timeline
-
Bill Ackman Confirms Valeant (VRX) Merger Plans on Allergan (AGN) - 13D
-
Allergan, Inc. (AGN) Surges on Ackman, Valeant Takeover Interest

